Tenax Therapeutics Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against Tenax Therapeutics, targeting investors who bought TENX shares over a nearly three-year window.
Law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, with a lead plaintiff deadline set for December 28, 2026.
Investors who purchased TENX securities between November 13, 2023, and August 7, 2026, may be eligible to participate in the lawsuit and potentially recover financial losses sustained during that period. The roughly three-year class period suggests the complaint centers on alleged misstatements or omissions that may have affected the stock's value over an extended stretch.
Read more Settle Lands Up to $100M Credit Facility From 3Jane for Inventory Financing →
The lawsuit seeks to recover damages on behalf of affected shareholders. Securities class actions of this type typically allege that a company or its executives misled investors through false or misleading statements, which artificially inflated or otherwise distorted the stock price during the defined class period. The legal action does not establish wrongdoing, and Tenax Therapeutics has not yet issued a public response to the filing as of this report.
Shareholders who believe they suffered losses tied to their TENX holdings during the specified window are encouraged to contact the law firm ahead of the December 2026 deadline to discuss potential eligibility for lead plaintiff status. Lead plaintiffs generally have the largest financial stake in the outcome and direct the litigation on behalf of the broader class.
Continue reading at All Financial Services & Investing.
